EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Avadel Pharmaceuticals's Enterprise Value is $1,536.10 Mil.
Avadel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-150.89 Mil. Therefore, Avadel Pharmaceuticals's EV-to-EBIT for today is -10.18.
The historical rank and industry rank for Avadel Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
AVDL'
s EV-to-EBIT Range Over the Past 10 Years
Min: -37.88 Med: 0.59 Max: 841.3
Current: -10.25
During the past 13 years, the highest EV-to-EBIT of Avadel Pharmaceuticals was 841.30. The lowest was -37.88. And the median was 0.59.
AVDL's EV-to-EBIT is ranked worse than 100% of 670
companies
in the Drug Manufacturers industry
Industry Median: 17.185
vs AVDL: -10.25
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Avadel Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $1,165.89 Mil.
Avadel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-150.89 Mil. Avadel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -12.94%.
Avadel Pharmaceuticals EV-to-EBIT Historical Data
The historical data trend for Avadel Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avadel Pharmaceuticals EV-to-EBIT Distribution
For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Avadel Pharmaceuticals's EV-to-EBIT falls into.
Avadel Pharmaceuticals EV-to-EBIT Calculation
Avadel Pharmaceuticals's EV-to-EBIT for today is calculated as:
Avadel Pharmaceuticals's current Enterprise Value is $1,536.10 Mil.
Avadel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-150.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Avadel Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $1,165.89 Mil.
Avadel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-150.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avadel Pharmaceuticals EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Avadel Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Avadel Pharmaceuticals (Avadel Pharmaceuticals) Business Description
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVDL has been successfully added to your 